InvestorsHub Logo

stockfan100

05/23/17 10:30 PM

#93088 RE: mariosmack #93083

This is just a baseless speculation. Company never said the product will be out in 2018!

First they say that the product will be out in March. Then September, now 2018.



Savvy investors know that line is "standard practice" for majority of companies filing SEC.

I'm talking about the official SEC filings, the ones they can't lie on.
OWCP admits that there is a very good chance of failing and collapsing.

BAMF31

05/23/17 11:36 PM

#93103 RE: mariosmack #93083

Can you provide the 3 links or specific filings from the company stating when the product release would be per as you state March, September and now 2018? I don't remember that the company stated any that for any of those time frames. What I remember is that the market readiness would be Q2 2017 and the product readiness would realistically be Q3 2017. There is a difference between market readiness and product readiness... Took this from FELLER... “Market Ready” often means getting everything in place, organized, marketing, packaging design, etc. Lots of initial stuff before production and distribution. Whereas “Product Readiness” is technically the final stage in getting a product actually approved for distribution to retailers and/or consumers. We are not in Q3 yet so how can you state that the company has delayed the product release yet?

skitahoe

05/24/17 12:11 AM

#93112 RE: mariosmack #93083

This language is essentially boiler plate and can be found in practically every quarterly report of most companies, even many who're currently profitable.

Probably the biggest reason I invested in OWCP was the belief that their business plan, which includes products that do, and don't require full FDA efficacy approval would work. I know that registrational Phase 2 or regular Phase 3 trials can cost hundreds of millions, but if the product is already selling, or other products are selling, much of the trial costs will be paid for by sales, and the remainder could easily come from limited dilution at much higher stock prices.

The key is sales of products that are viewed as cannabis based nutriceuticals or cosmetics, which should be the case for both the psoriasis cream and the sublingual tablet. In reality, both of these products could be very lucrative without going for full drug approval, however by going for approval, the products once approved would become eligible for insurance coverage which would make the products available to many who might not be able to afford the over the counter products.

I cannot say that our products will be the answer to PTSD, MM, etc. but when you read the stories about Veteran's who get benefits from cannabis, but can't get it from the V.A. I think it's very likely that our sublingual pill will make the grade. As an FDA approved drug, it will be available everywhere, not just in State's where medical marijuana has been approved. Much the same can be said for autism, and other diseases where anecdotal evidence can often be found, but conventional medicine refuses to even give it a try. Once FDA Approval is established, or sufficient anecdotal evidence exists for courts to order insurance to pay, ours and other product will be viewed entirely differently.

A couple years ago I had lost substantial weight when undergoing chemo treatment in the hospital. Friends brought in some marijuana based candy they hoped would improve my appetite. When the nurses got word of this, they read me the riot act. I found the candy to weak in small doses to do anything for me, but found the answer to my weight loss, it was getting off hospital food. I'm still on a form of chemo, but it doesn't effect my appetite, but I'm gaining weight due to little exercise because it makes me feel so weak. Each time I've returned to the gym I wound up with pneumonia, it may have been a coincidence, but my trainer cautioned me about the germs found in even the cleanest gym. I don't know that any form of cannabis would make me feel stronger, but if I used it, perhaps I wouldn't care.

Gary